Zocor for heterozygous familial hypercholesterolaemia

The licence for Zocor (simvastatin) has been extended to include use in children and adolescents, 10-17 years of age, with heterozygous familial hypercholesterolaemia.

Boys should be Tanner stage II and above and girls at least 1 year post menarche.

A standard cholesterol-lowering diet should be started before treatment with simvastatin is initiated and continued during treatment.

View Zocor drug record

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic guidance for diabetic foot infection

New antibiotic guidance for diabetic foot infection

NICE has updated its guidance on the prevention and...

Drug shortages - live tracker

Drug shortages - live tracker

Added: co-fluampicil.
Use our constantly updated...

Further drug shortages prompt advice to consider unlicensed alternatives

Further drug shortages prompt advice to consider unlicensed alternatives

Prescribers are being advised to prioritise supplies...

Vaping still safer than smoking, say health bosses after report of severe lung injury